Current State of Therapeutics for HTLV-1

TT Wang; A Hirons; M Doerflinger; KV Morris; S Ledger; DFJ Purcell; AD Kelleher; CL Ahlenstiel

Journal article

Current State of Therapeutics for HTLV-1

TT Wang, A Hirons, M Doerflinger, KV Morris, S Ledger, DFJ Purcell, AD Kelleher, CL Ahlenstiel

Viruses | MDPI | Published : 2024

DOI: 10.3390/v16101616

Download PDF

Abstract

Human T cell leukaemia virus type-1 (HTLV-1) is an oncogenic retrovirus that causes lifelong infection in ~5–10 million individuals globally. It is endemic to certain First Nations populations of Northern and Central Australia, Japan, South and Central America, Africa, and the Caribbean region. HTLV-1 preferentially infects CD4+ T cells and remains in a state of reduced transcription, often being asymptomatic in the beginning of infection, with symptoms developing later in life. HTLV-1 infection is implicated in the development of adult T cell leukaemia/lymphoma (ATL) and HTLV-1-associated myelopathies (HAM), amongst other immune-related disorders. With no preventive or curative intervention..

View full abstract

University of Melbourne Researchers

Ashley Hirons Author

Marcel Doerflinger Author

Damian Purcell Author

Related Projects (2)

ADDRESSING THE MAJOR CHALLENGES IN HIV VACCINE AND CURE RESEARCH

HIV remains one of the defining global health challenge of our times. 37 million people are living with HIV with 2 million new infections ea..

HTLV-1 virology and pathogenesis

HTLV-1 is a lifelong infection of immune cells that sustains high infection rates up to 45% in key Australian communities. Despite HTLV-1 ca..

Grants

Awarded by National Institute of Mental Health

Funding Acknowledgements

T.T.W. is funded by an Australian Government Research Training Program Scholarship. S.L., A.D.K., and C.L.A. are funded by an NHMRC programme grant (APP1149990), a UNSW Rapid Response Research grant, the NSW RNA Production Research Network, and a philanthropic grant to the Immunotherapy Research Fund at the Kirby Institute. A.H. and D.F.J.P. are funded by the Australian NHMRC Ideas grant (GNT2004670) and Australian Centre for HIV and Hepatitis Virology Research (ACH4) Project Grants. M.D. is funded by the ACH4 and the Phyllis Connor Memorial Trust. K.V.M. is funded by NIH R01 1R01MH134389-01 NIMH.